CSL Behring UK has become a full member of the Association of the British Pharmaceutical Industry (ABPI).
CSL Behring is a global leader in the plasma protein biotherapies industry. It researches, develops, manufactures and markets biotherapies which are used to treat serious and rare conditions. In the UK it specialises currently in haematology and immunology.
Full membership of the ABPI supports the company in expressing its core vision and values – patient focus, innovation, integrity collaboration and superior performance – in the UK.
Christian Wiezsner CSL Behring’s General Manager, UK and Ireland, said: “Our decision to become a full ABPI member underlines our commitment to developing and supplying innovative medicines that will improve the lives of people with rare diseases.
“We look forward to playing an active role across the ABPI’s work and in helping to shape the future of the pharmaceutical industry.”
GBR-CRP-0270 April 2022